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BACKGROUND: Bendectin was the primary pharmaceutical treatment of nausea and vomiting of pregnancy (NVP) in the United States
until the early 1980s. Its manufacture was then discontinued after public allegations that it was causing birth defects. Subsequently,
meta-analyses of the many epidemiological cohort and case/control studies used to examine that hypothesis have demonstrated the
absence of a detectable teratogenic effect. This study presents an ecological analysis of the same hypothesis that examines specific
malformations. METHODS: Annual birth defect prevalence data for the 1970s to the 1990s have been obtained for specific birth defects
from the Center for Disease Control’s nationwide Birth Defect Monitoring Program. These data for the US have been compared graphically
to the annual US Bendectin sales for the treatment of NVP. Data have also been obtained for annual US rates for hospitalization for NVP.
The three data sets have been temporally compared in graphic analysis. RESULTS: The temporal trends in prevalence rates for specific birth
defects examined from 1970 through 1992 did not show changes that reflected the cessation of Bendectin use over the 1980–84 period.
Further, the NVP hospitalization rate doubled when Bendectin use ceased. CONCLUSIONS: The population results of the ecological
analyses complement the person-specific results of the epidemiological analyses in finding no evidence of a teratogenic effect from the use
of Bendectin. Birth Defects Research (Part A) 67:88–97, 2003. © 2003 Wiley-Liss, Inc.
INTRODUCTION
From time immemorial, women have complained of the
discomforts of “morning sickness,” the colloquial term for
the condition that is medically referred to as nausea and
vomiting of pregnancy (NVP). The condition is character-
ized by symptoms ranging from nausea without vomiting
to nausea and severe vomiting, known as hyperemesis
gravidarum (HG). Severity of the condition ranges from
mild-moderate to most severe. Prevalence rates of this
condition among pregnant women have been reported as
50–90% (Gadsby, 1993; Tierson et al., 1986). The onset of
NVP symptoms usually occurs at about 40 days after the
last menstrual period (LMP); cessation generally follows at
about 85 days post-LMP. The impact of NVP on the
women who suffer from it can be social and emotional as
well as physical. Doctors often have differing opinions on
treatments of NVP cases. They generally advise women to
change their diet. Anti-emetics may also be prescribed.
Severe cases of NVP may lead to hospitalization for rehy-
dration and for treatment with anti-emetic, psychotropic,
or sedating pharmaceutical agents.
In 1956, the drug Bendectin was introduced into the US
market specifically for the treatment of NVP. Bendectin
sales grew steadily throughout the 1960s and 1970s and it
quickly became the leading treatment for NVP in the US. In
the UK it was marketed as Debendox and in Germany as
Lenotan. The original formulation of the drug, used until
November 1976, contained dicyclomine HCl (an antispas-
modic), doxylamine succinate (an antihistaminic), and pyr-
idoxine HCl (Vitamin B6). The drug was reformulated in
1976 with the removal of dicyclomine (FDA Drug Bulletin,
1981; Lamm, 1984).
By 1980, one-quarter to one-third of pregnant women in
the United States were using Bendectin during their preg-
nancy. Beginning in 1980, however, lawsuits and television
programs began to allege that Bendectin was a significant
human teratogen, calling it “The Second Thalidomide.”
Soon after this media coverage began, doctors and preg-
nant women nationwide became concerned about the pos-
sible effects of Bendectin use on the developing fetus, and
a large number of lawsuits ensued. Plaintiffs claimed that
Bendectin use had resulted in birth defects, primarily limb
reduction defects, in infants exposed to Bendectin in utero.
In June 1983, the manufacturer of Bendectin discontinued
its production, citing the increased insurance cost of main-
taining such a litigious drug on the market. Although the
use of Bendectin for the treatment of NVP ceased in the US
in June 1983, NVP continues to be a problem for pregnant
women.
The circumstances surrounding the popularity and de-
cline of Bendectin use provide an opportunity to examine,
in an “unnatural” or “unplanned” experiment, the hypoth-
esis that Bendectin was a significant teratogenic agent for
humans. If Bendectin was a causative teratogenic agent, as
has been alleged, one would expect to see an effect on
nationwide rates of birth defects during this time period.
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That is, if Bendectin were a human teratogen used by a
large proportion of pregnant women, the cessation of its
use should have lead to a reduced frequency of specific
birth defects. The Center for Disease Control’s Birth Defect
Monitoring Program, including nationwide data for 1970–
92, provided an appropriate database for examining this
phenomenon. The temporal comparison of the birth prev-
alence rates of specific birth defects with data on Bendectin
usage serves as the core analysis for this report. This is an
extension of the report and analysis originally submitted to
the US court system in 1984 when one of the authors (SHL)
served as a court-appointed expert in epidemiology in the
“Bendectin” product liability litigation (Lamm, 1984).
BACKGROUND
Numerous epidemiological studies have been conducted
to investigate the possible association between birth de-
fects and in utero exposure to Bendectin. Some of these
studies have reported a statistically significant positive
association between Bendectin and a specific birth defect or
birth defect group (Rothman et al., 1979; Eskenazi and
Bracken, 1982; Golding et al., 1983; Aselton, 1984). Other
studies have reported a statistically significant negative
association between Bendectin and a specific birth defect or
birth defect group (Fleming et al., 1981, Mitchell et al.,
1981). Most studies, however, have produced many non-
significant findings.
Two meta-analyses have been published, both of which
found that the association between Bendectin use and the
prevalence of birth defects was no different from 1.0 (Ein-
arson et al., 1988; McKeigue et al., 1994). The meta-analyses
were performed both on the “all malformations” or “all
major malformations” data and on “organ-specific malfor-
mations” data, based on cohort or case-control studies.
The published epidemiological studies seldom ad-
dressed specific types of malformations. Cohort studies to
examine rare events need to be quite large. Case/control
studies generally need an investigator with a specific in-
terest in a specific malformation. This study provides an
analysis of the relationship between Bendectin use and the
birth prevalence of various specific birth defects in the
United States using annual nationwide data both for Ben-
dectin use and for specific birth defects. This is an ecolog-
ical analysis, as the individual exposure characteristics of
the observed cases are not known.
Nearly two decades have passed since the Bendectin era
of treatment for NVP. Changes in the pharmacological
treatment of NVP patients and their need for hospitaliza-
tion can now be analyzed.
MATERIALS AND METHODS
To assess the temporal relationship between Bendectin
usage and birth defect rates, nationwide (USA) sources for
such data were sought. Three sources for measuring the
temporal trend in Bendectin usage were identified: one
based on drug mentions in physician office visits, one on
pharmacy data, and one on manufacturing data. The na-
tionwide birth defect surveillance system at the Center for
Disease Control (CDC) provided the temporal measure of
outcome (specific birth defects).
Exposure Data: Bendectin Use
Initial data on nationwide Bendectin use was gathered
from three sources: 1) the National Center for Health Sta-
tistics’ (NCHS) National Ambulatory Medical Care Survey
(NAMCS) that estimates diagnosis-specific drug mention
rates for physician office visits; 2) a Merrell-Dow Pharma-
ceuticals, Inc. estimation of New Therapy Starts; and 3) the
Food and Drug Administration (FDA) manufacturer’s re-
ports that include the number of Bendectin tablets sold per
year in the United States.
Between 1980 and 1990, the National Center for Health
Statistics (NCHS) conducted five surveys on medical care
in ambulatory practices. These surveys, collectively known
as the National Ambulatory Medical Care Survey
(NAMCS), were conducted in 1980, 1981, 1985, 1989, and
1990, and their data are available on public use data tapes
from the NCHS. The NAMCS is a sample-based database
of patient visits to non-federally employed physicians clas-
sified by the American Medical Association (AMA) as
“office-based, patient care” physicians. Patient visit data
do not include consultations outside of the physician’s
office, over the telephone, or in a hospital or institutional
setting. The NAMCS includes information regarding all
drugs or medications ordered, administered, or provided
during the visit. The AMA Drug Evaluation classifications
were used to identify anti-emetics (including anti-motion
sickness) drugs. The specific anti-emetics prescribed for all
diagnoses of normal pregnancy and NVP were recorded as
“drug mentions.” These included both Bendectin and non-
Bendectin anti-emetics used during pregnancy
An annual estimate of New Therapy Starts of Bendectin
usage was developed for Merrell-Dow Pharmaceuticals,
Inc. and submitted in litigation to the Southern District of
Ohio United States District Court. The estimate of Bendec-
tin New Therapy Starts was based on the 1961–1983 Ben-
dectin data from the National Disease and Therapeutic
Index (NDTI), published by IMS America, and the absence
of Bendectin distribution after 1984. The NDTI contains
information regarding drugs prescribed by private practi-
tioners in the United States, include both civilian and mil-
itary usage. Initial prescriptions were distinguished from
repeat (follow-up) prescriptions. The New Therapy Starts
data represent an annual approximation of the number of
women initiating treatment with Bendectin.
Pharmaceutical companies have been required since
1974 to report annually to the US Food and Drug Admin-
istration (FDA) the number of tablets distributed for each
of their products. The data that were reported to the FDA
for annual Bendectin tablet distribution were obtained.
These data on total US Bendectin sales (civilian plus mili-
tary) were used in the analyses that follow.
Outcome Data: Congenital Malformations
Beginning in 1970, the Birth Defect Monitoring Program
(BDMP) of the Centers for Disease Control and Prevention
(CDC) maintained a nationwide surveillance system of
birth defects. The BDMP monitored birth defect data
through hospital discharge records. Annual rates for spe-
cific congenital malformations were developed using the
data from this surveillance system.
The BDMP data were collected from coded hospital
discharge abstract forms through either the Commission
on Professional and Hospital Activities (CPHA) or the
McDonald-Douglas Health Information System (MDHIS).
The CPHA data on birth defects among live and stillborn
newborns has, since 1970, covered 15.5 million births from
1,200 hospitals. The MDHIS data on birth defects among
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live newborns from 1982–88 covered 2.9 million births
from about 900 hospitals. The BDMP database included
about 22% of the US births occurring from 1970–91. Al-
though the BDMP is neither a random nor a representative
sample of US births, it is the largest body of information on
US birth defects consistently collected. The BDMP data is
coded to the ICD-9-CM, modified by the British Pediatric
Association adaptation. The data is reported for 161 birth
defect categories. The data on 38 of these birth defect
categories were considered by the CDC to have sufficient
numbers to maintain statistical stability over time. Twenty-
five of these 38 defect categories have been considered
relevant to this study and are included in the analysis
(Table 1). The outcomes have been grouped into eight
distinct categories: central nervous system, cardiac, facial
cleft, gastrointestinal, genital tract, limb malformations,
genetic, and third trimester defects.
Outcome Data: Hospitalization for NVP
The National Center for Health Statistics develops an-
nually a public use data tape of hospital discharge data.
These data are from non-institutional (short-stay general
and specialty) hospitals, exclusive of military and Veterans
Administration hospitals, located in the 50 states and the
District of Columbia. These data tapes can be used to
determine the annual estimated frequency of hospitaliza-
tions for NVP or HG (coded as 643, i.e., excessive vomiting
in pregnancy).
Analytic Methods
This study presents an ecological graphic analysis of
temporal data for Bendectin use, birth defect birth preva-
lence rates, and hospitalizations for NVP that covers both
the time period when Bendectin was the major pharmaco-
logic treatment for NVP and the time period when Ben-
dectin was no longer available in the United States. As
mentioned earlier, three measures of Bendectin usage or
exposure are available for comparison. The annual data on
Bendectin New Therapy Starts and on Bendectin tablet
sales are available as continuous data. The data on anti-
emetic use for NVP from the NAMCS is only available as
intermittent data in the 1980–90 time period. The trends in
Bendectin use represented by these three data sets are
compared graphically in Figure 1.
The US birth prevalence of individual birth defects are
presented in temporal graphic analyses (Figs. 2–9) as con-
tinuous annual data. The specific birth defects are orga-
nized and presented by groups, such as organ systems.
Within each group, the temporal patterns of the specific
birth defects are compared graphically with the temporal
pattern of Bendectin sales data, which are used as a mea-
sure of the usage of Bendectin in the US.
A comparison of all anti-emetic treatments for NVP is
given to show the use of Bendectin in comparison with
other anti-emetics (Fig. 10). The annual US rate of hospi-
talization for NVP is also presented as a temporal graphic
analysis of continuous annual data (Fig. 11). Finally, the
temporal patterns of the Bendectin usage, the birth defect
data, and the hospitalizations for NVP are graphically
compared (Fig. 12).
Figure 1. Temporal patterns of Bendectin use in the United States,
1970–92.
Table 1
Birth Defect Monitoring Program (BDMP) and International Classification of Disease (ICD-9) Codes Used for the
Grouping of Congenital Malformations by Type
Category BDMP codes ICD-9 codes Malformations
CNS 045, 054, 065, 090, 100 740–742 Anencephaly, spina-bifida, hydrocephalus,
encephalocele, microcephalus
Cardiac 180, 200, 201, 215, 260 745–747 Transposition of great vessels, VSD, ASD, valve
stenosis and atresia, PDA
Facial cleft 325, 326, 327 749.0–749.2 Cleft palate, cleft lip, cleft palate with cleft lip
Gastro-intestinal 375, 393, 395 750.3, 751.2 Trach/esoph. Fistula, rectal atresia & stenosis, rectal &
anal dist. necrosis
Genital tract 412, 413 752 Undescended testicle, hypospadias
Limb malformations 472, 481–483, 490 755.2–755.4 Club foot w/o CNS defects, polydactyly, syndactyly,
reduction, hip dislocation
Genetic 626, 628, 630 758.0–758.8 Down syndrome, non-Down syndrome, autosomal
defect, sex chromosome defect
Third trimester 695, 943, 999 771, 779.9, 773 Total monitored infections, stillbirth, RH hemolytic NB
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RESULTS
Measures of Bendectin Usage
The temporal patterns of Bendectin use are presented in
Figure 1. All three data sources, the NAMC drug mention
data, New Therapy Starts, and the number of tablets sold,
show a similar downward trend of usage from 1980–84.
Bendectin sales data are a direct measure of the annual
sales of Bendectin, whereas New Therapy Starts and drug
mentions are estimated data. By definition, Bendectin sales
data are the number of tablets distributed from the man-
ufacturing plant annually for domestic consumption. New
Therapy Starts are a calculated annual estimate based on
prescription data from a varying set of pharmacies, and
drug mentions are a calculated intermittent estimate on a
statistical sampling of physician’s offices. Despite the dif-
ferent ways in which these data were gathered, the three
measures of Bendectin use present a consistent temporal
pattern of Bendectin use in the US for the 1970s and 1980s.
Congenital Malformations and Bendectin Use
Table 2 summarizes the general upward or downward
trends in the birth prevalence rates of birth defects from
1970 to 1992, according to the BDMP data. The birth prev-
alence rate for each malformation has been reported by
BDMP for each year. The range of the annual birth prev-
alence rates for each specific malformation is shown as
well as the mean birth prevalence rate. The gross temporal
change in reported rates over the 23-year period is shown
for each specific malformation. Some malformation
groups, e.g., facial clefts, show no change in prevalence
over the time period. A few recorded malformations showed
a major reduction over the time interval. These malforma-
tions included certain CNS malformations, such as anenceph-
aly (71%) and spina bifida (51%), which are first-trimester
events, and stillbirths (81%), which is classified as a third
trimester condition. Others, such as cardiac defects, show
marked increases in reported rates. The strongest upward
trends were for cardiac malformations, especially the trans-
position of great vessels (383%), ventricular septal defect
(633%), and patent ductus arteriosus (1,751%).
Whereas Table 2 reports on the general trend in malfor-
mation reports over the extended time period, Table 3
examines the Bendectin hypothesis by comparing the prev-
alence rates before and after the dramatic downturn in
Table 2
Percent Change in Incidence of Birth Defects from 1970–1992*




Anencephaly 1.1 5.6 3.3 71%
Spina bifida 3.7 8.3 5.3 51%
Hydrocephalus 4.5 6.7 5.7 11%
Encephalocele 0.8 1.4 1.3 9%
Microcephalus 1.1 3.7 2.4 53%
Cardiac
Transposition of great vessels 0.6 2.9 1.3 383%
Ventricular septal defect/2,500 births 1.0 7.3 3.6 633%
Atrial septal defect 1.2 14.4 3.6 658%
Valve stenosis and atresia 1 7.3 3.3 564%
Patent ductus arteriosus/2,500 births 0.9 16.2 6.4 1751%
Facial clefts
Cleft palate without cleft lip 4.6 5.9 5.3 4%
Cleft lip without cleft palate 3.0 4.2 3.5 3%
Cleft palate with cleft lip 4.1 6.3 5.7 2%
Gastro-intestinal
Tracheo-esophageal fistula 1.4 3.4 2.1 79%
Rectal atresia and stenosis 3.0 4.2 3.6 20%
Genital tract
Undescended testicle/2,500 births 4.8 10.5 7.4 112%
Hypospadias/2,500 births 5.1 9.2 7.0 73%
Limb malformations
Clubfoot w/o CNS/5,000 births 11.6 15.9 12.7 2%
Polydactyly/5,000 births 8.7 13.2 10.8 25%
Syndactyly 5.3 8.3 6.7 45%
Reduction deformities 3.0 4.0 3.5 18%
Hip dislocation and subluxation 7 37.6 25 291%
Genetic
Down syndrome/2,500 births 7.4 10.5 8.6 30%
Non-Down autosomal/2,500 births 1.0 3.3 2.0 200%
Sex chromosome defect/2,500 births 0.5 1.7 0.9 100%
Third Trimester Outcomes
Monitored infections 3.1 15.0 6.1 220%
Rh hemolytic disease/2,500 births 3.0 11.2 4.9 71%
Stillbirth/1,000 births 2.0 12.1 7.4 81%
*Summary data from the Birth Defect Monitoring Program, by malformation type. Birth
prevalence per 10,000 births unless otherwise specified.
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Bendectin use. The birth defect rates during two specific time
periods are compared: the rate during the height of the Ben-
dectin era (1978–80) and the rate after its discontinuation
(1985–87). The percent change from the first period to the
second period is also given.
In the original presentation of these analyses to the
Court, New Therapy Starts had been used as the represen-
tative measure of the temporal pattern of Bendectin use;
these data had been certified by the manufacturer and
accepted as representative upon submission to the Court.
Examples of those graphic analyses have been recently
published by Brent (2001) can be compared to those pre-
sented here. In this ecological analysis, however, Bendectin
sales data was used as the measure of Bendectin use,
because: 1) the sales data were developed independent of
the judicial proceedings, and 2) it was collected contempo-
raneously by the Food and Drug Administration each year.
Figure 1 demonstrated that the temporal patterns of the
two continuous measures are similar.
The NAMCS data was not used in the Court or in this
analysis as the measure of the temporal pattern of Bendec-
tin usage as it is relatively intermittent data (five data
points in 11 years). Nonetheless, its pattern is consistent
with those of the other two measures.
Figures 2–9 show ecologically the patterns of the birth
prevalence of each specific birth defect malformation
graphed over time in comparison to the temporal trend of
Bendectin sales as a measure of Bendectin usage.
Central Nervous System Malformations
Figure 2 demonstrates a noticeable decrease in CNS
malformations in the United States between 1970–92. Spe-
cifically, both anencephaly (71%) and spina bifida
(51%) show a large and continuous decrease, whereas
encephalocele shows a slight increase (9%). The annual
incidences of both anencephaly and spina bifida were de-
clining between 1970–79, a period during which Bendectin
sales did not show a similar decline. None of the moni-
tored central nervous system malformations show a tem-
poral pattern consistent with that of Bendectin use.
Across the period during which Bendectin came off the
market, notable decreases in anencephaly and spina bi-
Table 3









Anencephaly 3.53 2.43 31%
Spina bitida 5.30 4.63 13%
Hydrocephalus 5.07 6.33 25%
Encephalocele 1.17 1.10 6%
Microcephalus 2.17 2.60 20%
Cardiac
Transposition of the great vessel 0.90 1.50 67%
Ventricular septal defect 10.80 20.13 86%
Atrial septal defect 1.30 3.43 164%
Valve stenosis and atresia 1.37 5.47 299%
Patent ductus arteriosus 15.63 35.17 125%
Facial clefts
Cleft palate w/o cleft lip 5 5.6 12%
Cleft lip w/o cleft palate 3.5 3.4 2%
Cleft lip w/cleft palate 4.6 5.9 28%
Gastrointestinal
Tracheo-esophageal fistula 1.73 2.57 49%
Rectal atresia and stenosis 3.23 3.87 20%
Genital
Undescended testicles 24.47 36.10 48%
Hypospadias 30.00 32.70 9%
Limb
Clubfoot w/o CNS defects 24.90 25.33 2%
Polydactyly 20.67 23.20 12%
Syndactyly 6.57 7.47 14%
Reduction deformity 3.53 3.83 8%
Hip dislocation and subluxation 28.40 29.93 5%
Genetic
Down syndrome 7.77 9.57 23%
Autosomal abnormality (non-Down) 1.50 2.67 78%
Sex chromosome defect 0.70 1.20 60%
Third trimester
Total monitored infections 3.47 5.97 72%
Rh hemolytic disease 15.33 14.93 3%
Stillbirth 83.83 57.47 31%
*Summary data from the Birth Defect Monitoring Program, by malformation type. Birth prevalence
per 10,000 births unless otherwise specified.
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fida rates were observed as were increases in the rates
for hydrocephalus and microcephalus.
Cardiac Malformations
Figure 3 demonstrates a steady increase in cardiovascu-
lar malformations from 1970–92. All three malformations
show a significant increase, with patent ductus arteriosus
(PDA) rising 1,751% between 1970–92. These increases are
in direct opposition to the decline in Bendectin sales. Al-
though most of the cardiac defects were being reported
more frequently throughout the entire period, none of
these rates of increase was reflected downward contempo-
raneously with the drop in Bendectin use.
Facial Cleft Defects
Figure 4 demonstrates that each facial cleft defect inci-
dence rate remained relatively unchanged between 1970–
92. Both cleft palate (4%) and cleft palate with cleft lip (2%)
showed minor increases, whereas cleft lip showed a 3%
decrease.
Gastrointestinal Defects
Figure 5 demonstrates an increase in the annual inci-
dences of both tracheoesophageal fistulae (79%) and rectal
atresia and stenoses (20%) between the years 1970–92.
Neither of these trends resembles the Bendectin sales data.
Genital Tract Malformations
Figure 6 demonstrates a slight but steady increase in the
incidence of genital tract malformation from 1970–92. Both
undescended testicle (112%) and hypospadias (73%)
showed increases that do not resemble the drop in Bendec-
tin sales.
Limb Malformations
Figure 7 demonstrates that, of the limb malformations
analyzed, only clubfoot without CNS defects showed a
decrease (2%) in annual incidence between 1970–92. Poly-
dactyly (25%), syndactyly (45%), and limb reduction (18%)
each showed a notable increase. Hip dislocation and sub-
luxation showed a jagged increase in between 1974–79 that
declined sharply before the drop in Bendectin sales and
began to climb again after the cessation of its use; overall
hip dislocation and subluxation showed a dramatic 291%
increase between 1970–92. None of these trends indicate a
pattern similar to Bendectin sales.
Figure 2. Incidence of central nervous system defects (BDMP) and
Bendectin tablet sales in the United States, 1970–92.
Figure 3. Incidence of cardiac defects (BDMP) and Bendectin
tablet sales in the United States, 1970–92.
Figure 4. Incidence of facial anomalies (BDMP) and Bendectin
tablet sales in the United States, 1970–92.
Figure 5. Incidence of gastrointestinal defects (BDMP) and Ben-
dectin tablet sales in the United States, 1970–92.
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Genetic Malformations
Figure 8 demonstrates an increase in the incidence of
Down syndrome (30%), autosomal abnormalities exclud-
ing Down syndrome (200%), and sex chromosome abnor-
malities (100%) in the US from 1970–92. These increases do
not resemble the dramatic decrease in Bendectin sales seen
around 1980.
Third Trimester Defects
Figure 9 demonstrates that, although the annual inci-
dence of monitored infections increased 220%, this increase
occurred during 1987–1991. The incidence of Rh hemolytic
disease (71%) and stillbirths (81%) both show steady de-
clines in the US between the years of 1970–92. The decrease
in Rh hemolytic disease occurs primarily before 1980. The
incidence of stillbirth has been declining steadily since
1970.
Anti-Emetic Use in Pregnancy:
During and Post-Bendectin Era
The National Ambulatory Medical Care Survey
(NAMCS) provides an intermittent view of the use of
anti-emetics during pregnancy (1980 –90), including
both use of Bendectin and non-Bendectin anti-emetics.
The 1980 survey indicated that Bendectin accounted for
82% of the anti-emetic use for NVP (479,650 of 584,452
drug mentions). The 1981 survey indicated that Bendec-
tin accounted for 74.6% of the anti-emetic use for NVP
(310,214 of 415,657 drug mentions). Bendectin was not
mentioned in the anti-emetic use for NVP data in the
NAMCS reports for 1985, 1989, or 1990, although those
surveys had drug mention numbers of 69,683 for 1985,
103,592 for 1989, and 64,555 for 1990. Figure 10 demon-
strates the marked drop between 1981– 85 in anti-emetic
treatment for NVP. The use of anti-emetics dropped
about 90% between 1980 – 85, essentially due to the ab-
sence of Bendectin. The subsequent anti-emetic use has
remained at about 80,000 women per year, according to
the NAMCS data. Compazine, Phenergan, and Dra-
mamine were the major non-Bendectin anti-emetics
Figure 6. Incidence of genital defects (BDMP) and Bendectin tab-
let sales in the United States, 1970–92.
Figure 7. Incidence of limb malformations (BDMP) and Bendectin
tablet sales in the United States, 1970–92.
Figure 8. Incidence of genetic defects (BDMP) and Bendectin tab-
let sales in the United States, 1970–92.
Figure 9. Incidence of third trimester defects (BDMP) and Ben-
dectin tablet sales in the United States, 1970–92.
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cited. It is clear that the use of other anti-emetics did not
replace Bendectin in the treatment of NVP in the US.
Hospitalization Data for NVP:
During and Post-Bendectin Era
The NCHS public use data tapes on hospitalizations
have been analyzed to determine the annual estimated
number of hospitalizations for NVP in the US for the years
1974–94 (Fig. 11). From 1974–80, the number of hospital-
izations for NVP has stayed remarkably steady at about
seven hospitalizations per 1,000 live births. From 1980–87,
the number of hospitalizations for NVP7 climbed steadily
from seven per 1,000 live births to about 15–16 per 1,000
live births. Subsequently, the rate has risen and fallen in
the range of 16–17 per 1,000 live births.
Bendectin Sales, Birth Defects, and NVP
Hospitalizations: During and Post-Bendectin Era
Three measures related to Bendectin therapy have been
examined temporally from the mid 1970s to the 1990s: the
sales of Bendectin, the prevalence of specific birth defects,
and the hospitalization rate for NVP. Figure 12 presents all
three simultaneously, with limb reduction defects repre-
senting birth defect prevalence. The three measures are all
data collected contemporaneously by government agencies
in the ordinary conduct of their work and independent of
the hypotheses examined here. The birth defect data were
collected by the Centers for Disease Control (CDC), and the
Bendectin sales data were collected by the Food and Drug
Administration (FDA). The National Hospital Discharge
Survey data were collected by the National Center for
Health Statistics (NCHS). This figure demonstrates that
concomitant with the withdrawal of Bendectin from the
marketplace and in the absence of a replacement, the rate
of NVP hospitalization doubled and the birth defect rate
(represented by limb reduction defects) remained steady.
DISCUSSION
The ecological investigation presented above was under-
taken with the assumption that if Bendectin were a causal
teratogenic agent, its discontinuation would have had a
noticeable contemporaneous effect on the birth prevalence
rates of associated birth defects in the US. Despite the
numerous limitations inherent in any ecological investiga-
tion, the lack of any evidence of a decrease in the incidence
of birth defects, in general or specifically, contemporane-
ously with the decrease and subsequent cessation of Ben-
dectin use in the US suggests the lack of an association.
It is recognized that many factors contribute to the an-
nual birth prevalence of birth defects. The increasing avail-
ability of screening techniques (e.g., alpha-fetal protein
measures), pre-natal diagnostic capabilities (e.g., chorionic
villa sampling, amniocentesis, and high contrast ultra-
sound), availability of first and second trimester induced
abortions, and increased use of folic acid all may be re-
flected in the decreasing birth prevalence rates for specific
malformations. Long-term changes in the reported rates
reflect both increased interest in the diagnosis and report-
ing of birth defects as well as changes in medical practice
and social policies that are directed toward the reduced
frequency of birth defects and to other aspects of repro-
ductive health. The decrease seen in the birth prevalence of
nervous system disorders most likely reflects the conse-
quences of screening programs for anencephaly and spina
bifida and subsequent decisions of parents to terminate a
pregnancy after alpha-fetal protein and ultrasound screen-
ing lead to a diagnosis of these conditions. Increases in the
sensitivity of neonatal diagnostic equipment to detect and
diagnose cardiac variations have probably led to their
greater diagnostic frequency and often to therapeutic as-
sistance. Neonatal diagnostic capabilities, particularly in
Figure 10. Anti-emetic treatments for nausea and vomiting of
pregnancy (National Ambulatory Medical Care Surveys [1980–90]
Drug Mentions).
Figure 11. NVP hospitalizations in US per 1,000 live births by year
(1974–90).
Figure 12. Public health data related to Bendectin therapy.
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neonatal cardiology, are clearly reflected in the increased
frequency of reported cardiac defects seen after 1980.
The National Ambulatory Medical Care Survey data
demonstrate that the decrease in the use of Bendectin was
not followed by a concomitant rise in the use of other
anti-emetic agents (Engle and Lamm, 1989; Jick and Gar-
rison, 1986). Thus, the lack of a decrease in the birth prev-
alence rate for limb reduction defects with the cessation of
Bendectin use cannot be explained by the substitution of
the use of an alternative and teratogenic anti-emetic. The
National Hospital Discharge Survey data demonstrate that
the US hospitalization rate for NVP doubled after the
reduction and subsequent cessation of Bendectin use. The
pattern of NVP hospitalization in Canada was similar to
that seen in the US when Bendectin sales also disappeared
from their marketplace during the 1980–85 period. In Can-
ada, however, Diclectin, a generic form of Bendectin, re-
mained on the market and in the 1990s, as the sales of
Diclectin markedly increased, the rate of NVP hospitaliza-
tion continued to fall (Neutel, 2000). The NVP hospitaliza-
tion patterns suggest that at a population level the use of
Bendectin or of Diclectin had been effective in the treat-
ment of NVP.
The development of data for ecological analyses at-
tempts to present results in a comparable manner. Figure
13 presents the Bendectin use, birth defect prevalence
rates, and NVP hospitalization rates temporally and com-
parably by normalizing each data set to the mean data for
the years 1974–76 as a base period. Limb reduction was
used as the representative birth defect, because limb re-
duction was the most common of the teratological claims
against Bendectin and the publicly hypothesized associa-
tion, based on public knowledge of the effects of Thalido-
mide. The specific limb reduction defect phocomelia, the
major birth defect associated with Thalidomide, has be-
come considered publicly as the sentinel defect of drug-
induced teratogenicity.
Figure 13 demonstrates that, despite the reduction and
cessation of Bendectin sales during the period of 1980–85,
the rate of birth defects (limb reduction defect) was unaf-
fected and the rate of NVP hospitalization doubled. This
graphic presentation of the temporal pattern of the public
health data lends itself to the interpretation that the eco-
logical data indicated that the Bendectin therapeutic regi-
men was both safe (no effect on birth defect prevalence)
and effective (doubling of NVP hospitalization rate). This
interpretation is, of course, open to the proviso that it is
based on an ecological presentation where the specific
exposure status of each case and each non-case is un-
known, i.e., susceptible to the ecological fallacy. Nonethe-
less, the pattern is quite consistent with the known purpose
for which the drug was taken and with the epidemiological
studies that have shown no teratological association.
Although the data presented here may be interpreted in a
variety of ways, this analysis was not designed to investigate
a direct causal relationship between Bendectin use and
specific congenital malformations, but rather to examine
the trend of birth defects relative to the usage of Bendectin.
The lack of a decrease in the birth prevalence of birth
defects concomitant with the decrease and subsequent ces-
sation of Bendectin use does not support the previously
hypothesized association between Bendectin and birth de-
fects.
Although an ecological analysis, such as the one pre-
sented above, does not contain the statistical precision
often found in a case/control or cohort study, this analysis
does provide an exploratory investigation into possible
relationships between Bendectin use and incidence of birth
defects by making use of the best available national data.
Epidemiologists tend to be more influenced by case/con-
trol and cohort studies in reaching a judgment that a
particular exposure is, or is not, related to a particular
outcome. With respect to the Bendectin/birth defect hy-
pothesis, the published meta-analyses of the case/control
and cohort studies (Einarson et al., 1988; McKeigue et al.,
1994) convinced the professional and regulatory commu-
nities to conclude that the data did not support the causal
hypothesis. In presenting the information to non-medical
audiences, ecological analyses are often more persuasive
than meta-analyses. In judicial hearings, where both the
epidemiological and ecological analyses of the Bendectin
data have been presented, the Court and the jury have
commented afterwards that the ecological analyses were
most meaningful for them. Judge Carl Rubin, for whom the
report was originally written, has described the graph of
the temporal patterns of Bendectin usage and limb malfor-
mations (see version published by Brent (2001) as the most
effective exhibit seen in his court; the jurors from the trial
also identified it as a decisive item in their determination
that Bendectin was not a human teratogen.
Too often, epidemiologists speak of “ecological fallacies”
without giving appropriate recognition to “ecological
truths.” Ecological analyses serve an important and com-
plementary role with epidemiological analyses in present-
ing public health information.
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